Neurocrine's INGREZZA Study Reports Better Daily Function in TD
Neurocrine Biosciences (NASDAQ: NBIX) said published Phase 4 KINECT-PRO results for INGREZZA (valbenazine) showed once-daily treatment improved patient-reported quality of life and daily functioning in adults with tardive dyskinesia over 24 weeks. In an open-label study (n=59; 45 efficacy), mean TDIS change was -8.0 and AIMS -6.8, both exceeding MCID thresholds, and 58% met clinician-defined symptomatic remission at Week 24.
How this was made
The 30-second read
Why it matters
The publication highlights clinically meaningful improvements across multiple validated patient-reported outcomes (TDIS, EQ-VAS, SDS) and clinician-rated AIMS, with a Week 24 remission rate and no new safety signals.
Market read
Investors may view the results as additional support for INGREZZA’s real-world value proposition, particularly around daily functioning and patient-reported burden.
What to watch
The sample size is modest (n=59; 45 in efficacy analyses) and the article does not quantify durability beyond Week 24 or provide comparative efficacy versus other therapies.
Background
Neurocrine Biosciences is marketing INGREZZA (valbenazine), a VMAT2 inhibitor, for tardive dyskinesia; KINECT-PRO is a Phase 4 study focused on patient-reported quality of life and daily functioning.
Ticker impact
Neurocrine published Phase 4 KINECT-PRO results showing once-daily INGREZZA improved patient-reported quality of life and daily functioning over 24 weeks.
Near-term upside bias for NBIX sentiment, but likely limited incremental impact versus prior clinical readouts since this is publication of already-known Phase 4 data.
Reported endpoints include TDIS and AIMS mean changes exceeding MCID, 58% clinician-defined symptomatic remission at Week 24, and no new safety concerns, which can reinforce the INGREZZA value proposition for investors.
Market effects
Reinforces the VMAT2 inhibitor evidence base and may support broader sentiment toward tardive dyskinesia treatment franchises.
No clear regional spillover beyond US-listed biotech sentiment.
Limited global read-through; clinical publication primarily affects company-specific positioning.
Counterpoint
Because the study is open-label and the article is a publication summary, the incremental market impact may be smaller than investors expect if the underlying data were already anticipated.
Key entities
- companyNeurocrine Biosciences
NASDAQ-listed company publishing Phase 4 KINECT-PRO findings for INGREZZA in tardive dyskinesia.
- drugINGREZZA (valbenazine)
VMAT2 inhibitor whose patient-reported and clinician-rated outcomes improved in the KINECT-PRO study.
- clinical_studyKINECT-PRO
Phase 4 open-label study evaluating quality of life and daily functioning over 24 weeks.
